Rachel M.A. Linger

1.5k total citations · 1 hit paper
12 papers, 1.2k citations indexed

About

Rachel M.A. Linger is a scholar working on Immunology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Rachel M.A. Linger has authored 12 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 3 papers in Molecular Biology and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Rachel M.A. Linger's work include Phagocytosis and Immune Regulation (5 papers), Cancer therapeutics and mechanisms (1 paper) and Technology Adoption and User Behaviour (1 paper). Rachel M.A. Linger is often cited by papers focused on Phagocytosis and Immune Regulation (5 papers), Cancer therapeutics and mechanisms (1 paper) and Technology Adoption and User Behaviour (1 paper). Rachel M.A. Linger collaborates with scholars based in United States. Rachel M.A. Linger's co-authors include Douglas K. Graham, Amy K. Keating, H. Shelton Earp, Kurtis D. Davies, Susan Goebel-Goody, Ronald K. Freund, Michael Browning, Deborah DeRyckere, Susan Sather and Christopher T. Cummings and has published in prestigious journals such as Blood, PLoS ONE and Oncogene.

In The Last Decade

Rachel M.A. Linger

11 papers receiving 1.2k citations

Hit Papers

TAM Receptor Tyrosine Kin... 2008 2026 2014 2020 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer
    2008 577 citations Rachel M.A. Linger, Amy K. Keating et al. Advances in cancer research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rachel M.A. Linger United States 8 796 359 254 165 154 12 1.2k
Peiyuan Lu China 14 634 0.8× 568 1.6× 500 2.0× 139 0.8× 72 0.5× 29 1.4k
Virginie Vives France 14 516 0.6× 678 1.9× 544 2.1× 95 0.6× 44 0.3× 18 1.4k
Denise Tischner Germany 22 517 0.6× 404 1.1× 181 0.7× 55 0.3× 75 0.5× 28 1.1k
Tomoo Ueno Japan 20 1.5k 1.9× 541 1.5× 512 2.0× 119 0.7× 113 0.7× 23 2.2k
Brian Niland United States 13 531 0.7× 467 1.3× 141 0.6× 283 1.7× 65 0.4× 18 1.4k
Sherri L. Rankin United States 16 644 0.8× 619 1.7× 260 1.0× 75 0.5× 71 0.5× 25 1.4k
Jennifer L. Berard Canada 9 321 0.4× 238 0.7× 134 0.5× 100 0.6× 71 0.5× 9 929
Stefanie Gaupp Germany 13 496 0.6× 205 0.6× 190 0.7× 146 0.9× 49 0.3× 17 1.0k
Caroline G. Humphries United States 13 318 0.4× 1.2k 3.2× 148 0.6× 120 0.7× 271 1.8× 17 1.7k
Balachandra K. Gorentla United States 21 769 1.0× 367 1.0× 150 0.6× 149 0.9× 191 1.2× 25 1.2k

Countries citing papers authored by Rachel M.A. Linger

Since Specialization
Citations

This map shows the geographic impact of Rachel M.A. Linger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel M.A. Linger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel M.A. Linger more than expected).

Fields of papers citing papers by Rachel M.A. Linger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel M.A. Linger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel M.A. Linger. The network helps show where Rachel M.A. Linger may publish in the future.

Co-authorship network of co-authors of Rachel M.A. Linger

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel M.A. Linger. A scholar is included among the top collaborators of Rachel M.A. Linger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel M.A. Linger. Rachel M.A. Linger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Payton, Mark E., et al.. (2024). Healthcare providers’ knowledge and attitudes about overdose prevention sites in Colorado. Harm Reduction Journal. 21(1). 155–155. 1 indexed citations
3.
4.
Zhong, Qing Peter Wild, et al.. (2023). Integrating Foundational and Clinical Science Remotely by Combining Team-Based Learning and Simulation. Medical Science Educator. 33(4). 925–934. 2 indexed citations
5.
Cummings, Christopher T., Rachel M.A. Linger, Susan Sather, et al.. (2014). Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget. 5(21). 10434–10445. 29 indexed citations
6.
Linger, Rachel M.A., Alisa B. Lee‐Sherick, Deborah DeRyckere, et al.. (2013). Mer receptor tyrosine kinase is a therapeutic target in pre–B-cell acute lymphoblastic leukemia. Blood. 122(9). 1599–1609. 47 indexed citations
7.
Linger, Rachel M.A., Richard A. Cohen, Christopher T. Cummings, et al.. (2012). Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 32(29). 3420–3431. 170 indexed citations
8.
9.
Lee‐Sherick, Alisa B., Rachel M.A. Linger, Lia Gore, Amy K. Keating, & Douglas K. Graham. (2010). Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. British Journal of Haematology. 151(4). 295–311. 31 indexed citations
10.
Linger, Rachel M.A., Amy K. Keating, H. Shelton Earp, & Douglas K. Graham. (2010). Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opinion on Therapeutic Targets. 14(10). 1073–1090. 133 indexed citations
11.
Goebel-Goody, Susan, Kurtis D. Davies, Rachel M.A. Linger, Ronald K. Freund, & Michael Browning. (2008). Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience. 158(4). 1446–1459. 161 indexed citations
12.
Linger, Rachel M.A., Amy K. Keating, H. Shelton Earp, & Douglas K. Graham. (2008). TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer. Advances in cancer research. 100. 35–83. 577 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peiyuan Lu Breakdown of academic impact, for papers by Virginie Vives Breakdown of academic impact, for papers by Denise Tischner Breakdown of academic impact, for papers by Tomoo Ueno Breakdown of academic impact, for papers by Brian Niland Breakdown of academic impact, for papers by Sherri L. Rankin Breakdown of academic impact, for papers by Jennifer L. Berard Breakdown of academic impact, for papers by Stefanie Gaupp Breakdown of academic impact, for papers by Caroline G. Humphries Breakdown of academic impact, for papers by Balachandra K. Gorentla
Rankless by CCL
2026